| Erbitux (cetuximab) / Eli Lilly, EMD Serono |
NCT00086892: Cetuximab and Carboplatin in Treating Patients With Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer |
|
|
| Completed | 2 | | Japan, US, Canada, Europe, RoW | cetuximab, carboplatin | Gynecologic Oncology Group, National Cancer Institute (NCI), Bristol-Myers Squibb | Ovarian Cancer, Primary Peritoneal Cavity Cancer | 04/06 | | | |
NCT00063401: Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer |
|
|
| Completed | 2 | 39 | US | Cetuximab:, Erbitux, Paclitaxel, Carboplatin | Eli Lilly and Company, Bristol-Myers Squibb | Ovarian Cancer, Peritoneal Neoplasms, Fallopian Tube Neoplasms | 06/06 | 06/06 | | |
NCT00082212: A Study in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma |
|
|
| Terminated | 2 | 25 | US | Cetuximab, Erbitux | Eli Lilly and Company, Bristol-Myers Squibb | Ovarian Cancer | 06/07 | 06/07 | | |
NCT00448097: Efficacy and Safety Study of Cetuximab or Cetuximab Plus Docetaxel to Treat Prostate Cancer Before Prostatectomy |
|
|
| Terminated | 2 | 7 | US | cetuximab, Erbitux, docetaxel, Taxotere | The Methodist Hospital Research Institute, Bristol-Myers Squibb, Eli Lilly and Company | Prostatic Neoplasms | 06/08 | 08/08 | | |
NCT00350025: Study of Cetuximab With and Without Weekly Paclitaxel for Patients With Previously Treated Advanced Urothelial Cancer |
|
|
| Completed | 2 | 41 | US | Cetuximab, Paclitaxel, Taxol | Fox Chase Cancer Center, Bristol-Myers Squibb | Urologic Neoplasm | 07/10 | 09/12 | | |
NCT00392769: Cetuximab in Patients With Progressive or Recurrent Endometrial Cancer |
|
|
| Completed | 2 | 33 | US | Cetuximab, C225, Erbitux™, IMC-C225 | M.D. Anderson Cancer Center, Bristol-Myers Squibb | Endometrial Cancer | 12/10 | 12/10 | | |
NCT00661492: Mitoxantrone ± Cetuximab 2nd Line Androgen Independent Prostate Cancer (AIPC) |
|
|
| Completed | 2 | 115 | US | cetuximab, Erbitux, Mitoxantrone, Novantrone | US Oncology Research, Eli Lilly and Company, Oregon Health and Science University | Androgen-independent Prostate Cancer | 03/11 | 06/11 | | |
NCT00645593: Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer |
|
|
| Completed | 2 | 89 | US | Gemcitabine,, Gemzar, Cisplatin, Cetuximab, Erbitux | University of Michigan Rogel Cancer Center, National Comprehensive Cancer Network, Bristol-Myers Squibb, Eli Lilly and Company | Bladder Cancer | 04/14 | 06/15 | | |
